𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The production of human papillomavirus type 16 L1 vaccine product fromEscherichia coliinclusion bodies

✍ Scribed by W. Lai; A. Middelberg


Publisher
Springer
Year
2002
Tongue
English
Weight
146 KB
Volume
25
Category
Article
ISSN
1615-7605

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Safety, immunogenicity, and efficacy of
✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naΓ―

Occurrence of antibodies TO L1, L2, E4 a
✍ Heinrich G. KΓΆchel; Masyar Monazahian; Kai Sievert; Michaela HΓΆhne; Christoph Th πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 French βš– 820 KB

Sera from I 18 women of 33 to over 90 years of age, with or without a history of cervical squamous-cell carcinoma, were examined for the presence of antibodies to HPV-6b, HPV-I6 and HPV-18 LI, U, E4, and E7 gene products by the use of bacterially derived P-Gal fusion proteins and Western-blot analys